Trends on epidemiological, virological, and clinical features among newly diagnosed HIV‐1 persons in Northwest Spain over the last 10 years

To describe temporal trend and characteristics of newly HIV‐diagnosed patients in a medical care area in Northwest Spain over the last 10 years. All newly diagnosed patients for HIV‐infection from 2004 to 2013 at a reference medical care area in Northwest of Spain were identified. Epidemiological, virological, immunological, and clinical data, as well as HIV genotype and drug resistance information were recorded. A total of 565 newly HIV‐diagnosed patients were identified. The number of new cases increased in the last 5 years (66 cases/year). Overall, 53.1% had a median CD4 counts < 350 cells/µl and 33.6% had an AIDS defining criteria. Non‐B variants were found in 34.4% of patients being subtype F (25.8%) the most common non‐B subtype. The rate of transmitted drug resistance (TDR) over the study period was 3.7%, but a decreased to 2.6% was observed in the last 5 years. The most prevalent TDR mutations were: T215 revertants (1.5%), K219QENR (1.2%), for NRTIs; K103N (1.9%), for NNRTIs; L90M (0.3%), for PIs. Overall, 73.2% of patients started antiretroviral treatment and 9.9% of patients died during follow‐up. The number of newly HIV diagnosed patients increased since year 2009. There is a high prevalence of late diagnosis (53%) and 33% had an AIDS defining criteria. Interestingly, the most prevalent non‐B subtype in our population was F (25.8%). These findings support the need to facilitate the access for HIV testing to reduce the rate of late HIV diagnosis, improve the clinical outcome and prevent HIV transmission. J. Med. Virol. 87:1319–1326, 2015. © 2015 Wiley Periodicals, Inc.

[1]  E. Poveda,et al.  High prevalence of subtype F in newly diagnosed HIV-1 persons in northwest Spain and evidence for impaired treatment response , 2014, AIDS.

[2]  C. Vidal,et al.  Clinically Relevant Transmitted Drug Resistance to First Line Antiretroviral Drugs and Implications for Recommendations , 2014, PloS one.

[3]  G. Ippolito,et al.  The potential impact of routine testing of individuals with HIV indicator diseases in order to prevent late HIV diagnosis , 2013, BMC Infectious Diseases.

[4]  A. Brown,et al.  Quality of HIV care in the United Kingdom: key indicators for the first 12 months from HIV diagnosis , 2013, HIV medicine.

[5]  Hongzhou Lu,et al.  Analysis of the immunologic status of a newly diagnosed HIV positive population in China , 2013, BMC Infectious Diseases.

[6]  J. Casabona,et al.  Who are the men who have sex with men in Spain that have never been tested for HIV? , 2013, HIV medicine.

[7]  V. Moyer,et al.  Screening for HIV: U.S. Preventive Services Task Force Recommendation Statement , 2013, Annals of Internal Medicine.

[8]  M. Chironna,et al.  Surveillance of new HIV infections/diagnoses in Puglia region (south Italy), years 2007-2011. , 2013, Annali di igiene : medicina preventiva e di comunita.

[9]  B. Suligoi,et al.  Late presenters among persons with a new HIV diagnosis in Italy, 2010–2011 , 2013, BMC Public Health.

[10]  Y. Yazdanpanah,et al.  Increasing HIV-1 non-B subtype primary infections in patients in France and effect of HIV subtypes on virological and immunological responses to combined antiretroviral therapy. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  Klaus Korn,et al.  HIV-1 subtype distribution and its demographic determinants in newly diagnosed patients in Europe suggest highly compartmentalized epidemics , 2013, Retrovirology.

[12]  H. Salomón,et al.  Increasing trends in primary NNRTI resistance among newly HIV-1-diagnosed individuals in Buenos Aires, Argentina , 2013, Journal of the International AIDS Society.

[13]  F. García,et al.  Analysis of transmitted drug resistance in Spain in the years 2007-2010 documents a decline in mutations to the non-nucleoside drug class. , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[14]  M. Zazzi,et al.  HIV-1 Subtype F1 Epidemiological Networks among Italian Heterosexual Males Are Associated with Introduction Events from South America , 2012, PloS one.

[15]  M. Thomson,et al.  Rapid expansion of a HIV-1 subtype F cluster of recent origin among men who have sex with men in Galicia, Spain. , 2012, Journal of acquired immune deficiency syndromes.

[16]  L. Held,et al.  Improved virological outcome in White patients infected with HIV-1 non-B subtypes compared to subtype B. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  Deirdre L Church,et al.  HIV-1 viral diversity and its implications for viral load testing: review of current platforms. , 2011, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[18]  M. Leal,et al.  Prevalence and resistance mutations of non-B HIV-1 subtypes among immigrants in Southern Spain along the decade 2000-2010 , 2011, Virology Journal.

[19]  V. Soriano,et al.  Changing rate of non-B subtypes and coinfection with hepatitis B/C viruses in newly diagnosed HIV type 1 individuals in Spain. , 2011, AIDS research and human retroviruses.

[20]  David Dunn,et al.  Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. , 2011, The Lancet. Infectious diseases.

[21]  P. Ghys,et al.  Global trends in molecular epidemiology of HIV-1 during 2000–2007 , 2011, AIDS.

[22]  Burkhard Morgenstern,et al.  The role of recombination in the emergence of a complex and dynamic HIV epidemic , 2010, Retrovirology.

[23]  B. Gazzard,et al.  Late diagnosis in the HAART era: proposed common definitions and associations with mortality , 2010, AIDS.

[24]  A. Mocroft,et al.  Medical and Societal Consequences of Late Presentation , 2010, Antiviral therapy.

[25]  E. Poveda,et al.  Changes in drug resistance patterns following the introduction of HIV type 1 non-B subtypes in Spain. , 2009, AIDS research and human retroviruses.

[26]  R. Maserati,et al.  Prevalence of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy: evolution over 12 years and predictors. , 2009, The Journal of antimicrobial chemotherapy.

[27]  R. Rodrigues,et al.  High prevalence and association of HIV-1 non-B subtype with specific sexual transmission risk among antiretroviral naïve patients in Porto Alegre, RS, Brazil. , 2009, Revista do Instituto de Medicina Tropical de Sao Paulo.

[28]  S. Baral,et al.  The global epidemic of HIV infection among men who have sex with men , 2009, Current opinion in HIV and AIDS.

[29]  T. de Oliveira,et al.  Genetic variability of human immunodeficiency virus‐1 in Bahia state, Northeast, Brazil: High diversity of HIV genotypes , 2009, Journal of medical virology.

[30]  H. Gunthard,et al.  Update of the Drug Resistance Mutations in HIV-1. , 2008, Topics in HIV medicine : a publication of the International AIDS Society, USA.

[31]  A. Tanuri,et al.  Drug Resistance Mutation Profile and Accumulation Kinetics in Human Immunodeficiency Virus-Positive Individuals Infected with Subtypes B and F Failing Highly Active Antiretroviral Therapy Are Influenced by Different Viral Codon Usage Patterns , 2008, Antimicrobial Agents and Chemotherapy.

[32]  M. Márquez,et al.  Prevalencia de mutaciones de resistencia primaria en los nuevos diagnósticos de infección por el VIH en la provincia de Málaga , 2008 .

[33]  D. Goldberg,et al.  HIV subtypes in Scotland, 2000–2006 , 2007, Epidemiology and Infection.

[34]  R. Kaiser,et al.  Trends of prevalence of primary HIV drug resistance in Germany. , 2007, The Journal of antimicrobial chemotherapy.

[35]  B. Gazzard,et al.  Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count , 2007, AIDS.

[36]  Atlanta,et al.  Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. , 2006, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[37]  M. Weinstein,et al.  Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[38]  JD Lundgren,et al.  Updated European Recommendations for the Clinical Use of HIV Drug Resistance Testing , 2004, Antiviral therapy.

[39]  P. Kissinger,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. , 1998, The New England journal of medicine.

[40]  G. Ippolito,et al.  Association between HIV‐1 infection and miscarriage: a retrospective study , 1998, AIDS.

[41]  F. Brun-Vézinet,et al.  HIV‐1 diversity in Romania , 1998, AIDS.

[42]  G. Satten,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.

[43]  R. Evans European Centre for Disease Prevention and Control. , 2014, Nursing standard (Royal College of Nursing (Great Britain) : 1987).

[44]  V. Soriano,et al.  HIV-1 genotypic drug resistance interpretation rules - 2009 Spanish guidelines. , 2009, AIDS reviews.

[45]  Panel de expertos de Gesida,et al.  [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update January 2007)]. , 2007 .

[46]  U. Bauer,et al.  [Centers for Disease Control and Prevention (CDC)]. , 2000, Annales de dermatologie et de venereologie.